Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Wednesday, April 1, 2026
Cyclerion’s $380 Million Merger with Korsana Biosciences
Tuesday, March 31, 2026
ONCOMATRYX’s $67 Million Fund Raise
SCYNEXIS’s $40 Million Private Placement
TippingPoint’s $4 Million Seed Round
Semarion’s $4 Million Fund Raise
Lilly’s Acquisition of Centessa Pharmaceuticals
Biogen Acquisition of Apellis Pharmaceuticals
Monday, March 30, 2026
Connect’s $20 Million Private Placement
Quince’s $16 Million Debt Financing
Artelo’s $11 Million Private Placement
Aurinia’s Acquisition of Kezar Life Sciences
Friday, March 27, 2026
Otsuka’s $700 Million Acquisition of Transcend Therapeutics
OnKure’s $150 Million Private Placement
Zenas’s $200 Million Public Offerings and Debt Financing
Vor’s $75 Million Private Placement
Stratum’s $2 Million Seed Round
Thursday, March 26, 2026
Pinnacle’s $89 Million Series B
Terrestrial’s $50 Million Series C
Wednesday, March 25, 2026
Merck’s $6.7 Billion Acquisition of Terns Pharmaceuticals
Endogenex ‘s $50 Million Series C
Tuesday, March 24, 2026
Gilgamesh’s $60 Million Series A
EpiFrontier’s $32 Million Grant
Karyopharm’s $30 Million Private Placement
Turn’s $25 Million Debt Financing
Rybodyn’s $10 Million Seed Round
RenovoRx’s $10 Million Private Placement…More
Outlook’s $5 Million Public Offering
Sernova’s $2 Million Private Placement
Monday, March 23, 2026
Reviva’s $10 Million Public Offering…More
Tempest’s $6 Million Private Placement
Friday, March 20, 2026
Earendil’s $787 Million Venture Financing
Hansa’s $30 Million Debt Financing
Bioxytran’s $1 Million Private Placement
Thursday, March 19, 2026
SAB’s $85 Million Public Offering
Humacyte’s $20 Million Registered Direct Offering
Azitra’s $10 Million Private Placement
Wednesday, March 18, 2026
Crossbow’s $77 Million in Series B
Excalipoint’s $69 Million Seed Round
Ovid’s $60 Million Private Placement
Serina’s $30 Million Private Placement
Kupando’s $27 Million Series A
Tuesday, March 17, 2026
Monday, March 16, 2026
CytomX’s $250 Million Public Offering
Alto’s $120 Million Private Placement
Unnatural’s $45 Million Series B
Acumen’s $36 Million Private Placement
Outlook’s $18 Million Debt Financing
Friday, March 13, 2026
Indivior’s $450 Million Debt Financing
Equillium’s $35 Million Private Placement
Cinclus’s $32 Million Venture Financing
Thursday, March 12, 2026
Dianthus’s $719 Million Public Offering…More, More
Wednesday, March 11, 2026
Longeveron’s $30 Million Private Placement
Tuesday, March 10, 2026
Xenon’s $650 Million Public Offering
BioXcel’s $8 Million Registered Direct Offering
MindImmune’s $5 Million Venture Financing
Monday, March 9, 2026
Relmada’s $160 Million Private Placement
Korro’s $85 Million Private Placement
Lyell’s $50 Million Private Placement
AN2’s $40 Million Private Placement
Calidi’s $6 Million Public Offering…More
Friday, March 6, 2026
Shuttle’s $3 Million Public Offering
Rakovina’s $1 Million Private Placement
Thursday, March 5, 2026
Cognito’s $105 Million Series C
Atavistik’s $40 Million Series B
CytoDyn’s $17 Million Private Placement
Wednesday, March 4, 2026
Teva’s $400 Million Fund Raise
MAIA’s $30 Million Public Offering
Sernova’s $20 Million Debt Financing
Can-Fite’s $4 Million Warrant Exercise
Tuesday, March 3, 2026
Prolium’s $50 Million Series A
Polares’s $50 Million Series C
Antiverse’s $9 Million Series A
Monday, March 2, 2026
Royalty’s $250 Million Royalty and Debt Financing
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.